Dompen

Dompé is a leading Italian biopharmaceutical company focused on the development of innovative therapeutic solutions for diseases with high unmet medical needs. The company is best known for its breakthrough research in the field of ophthalmology, specifically the development of Oxervate (cenegermin), the first ever topical biologic for neurotrophic keratitis based on Nerve Growth Factor (NGF) research. Beyond ophthalmology, Dompé maintains a robust pipeline in oncology, pain management, and metabolic diseases, leveraging its proprietary Exscalate platform for structure-based drug design. Headquartered in Milan, the company operates globally with a significant presence in the United States and Europe, integrating R&D, manufacturing, and commercialization capabilities.